Exchange: NASDAQ·Updated 07:50 PM EDT
News
all
press releases
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Zacks
More News
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-timeread more...
Benzinga
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.read more...
Benzinga
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Why Did OTLK Stock Crash In Pre-Market Today?
Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.
Stocktwits
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
Zacks
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.
Zacks

Advertisement|Remove ads.